Gilead Sciences Inc
(BUE:GILD)
ARS
25950
-75 (-0.29%)
Market Cap: 105.89 Til
Enterprise Value: 126.07 Til
PE Ratio: 105.76
PB Ratio: 5.91
GF Score: 55/100 Gilead Sciences Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 25, 2021 / 06:40PM GMT
Release Date Price:
ARS2320
(+1.31%)
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst
Good afternoon, everybody, and welcome to this afternoon session of our Global Healthcare Conference. I'm delighted to welcome our next company, Gilead Sciences, I presume known to everybody on the call. From Gilead, we're joined by Johanna Mercier, Chief Commercial Officer; and Andy Dickinson, Chief Financial Officer.
Johanna and Andy, thank you for joining our conference today and appearing on screen at least from California.
Johanna Mercier
Gilead Sciences, Inc. - Chief Commercial Officer
Thanks for having us.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Thank you. Thanks for having us.
Questions & Answers
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst
So our format today is
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot